Timothy Kieffer, Ph.D.

Timothy Kieffer is Chief Scientific Officer of Fractyl Health. Tim has co-authored more than 200 publications on incretin hormones, islet biology, and gene therapies, and has been cited over 20,000 times.

He is a Professor of Medicine, Department of Cellular & Physiological Sciences and Department of Surgery, School of Biomedical Engineering, and Life Sciences Institute at the University of British Columbia, where his laboratory focuses on islet biology and the development of novel gene and cell therapy approaches to treat diabetes.

In 2021, Tim joined ViaCyte, a leader in stem cell therapies for Type 1 Diabetes, as its Chief Scientific Officer until ViaCyte’s acquisition by Vertex. He obtained his PhD at the University of British Columbia and completed a postdoctoral research fellowship at Massachusetts General Hospital.